Cargando…
Phase I clinical trial of AXL1717 for treatment of relapsed malignant astrocytomas: analysis of dose and response
PURPOSE: Early phase I study of safety of AXL1717 in patients with recurrent or progressive malignant astrocytomas and evaluation of preliminary anti-tumor efficacy. PATIENTS AND METHODS: Nine patients fulfilling the set criteria were enrolled. Eight had recurrent glioblastoma and one gliosarcoma. P...
Autores principales: | Aiken, Robert, Axelson, Magnus, Harmenberg, Johan, Klockare, Maria, Larsson, Olle, Wassberg, Cecilia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5655304/ https://www.ncbi.nlm.nih.gov/pubmed/29113409 http://dx.doi.org/10.18632/oncotarget.20662 |
Ejemplares similares
-
The Prognostic Value of Pre-Treatment Leukocytosis in Patients with Previously Treated, Stage IIIB/IV Non-Small Cell Lung Cancer Treated with the IGF-1R Pathway Modulator AXL1717 or Docetaxel; a Retrospective Analysis of a Phase II Trial
por: Holgersson, Georg, et al.
Publicado: (2017) -
The Axl-Regulating Tumor Suppressor miR-34a Is Increased in ccRCC but Does Not Correlate with Axl mRNA or Axl Protein Levels
por: Fritz, Helena K., et al.
Publicado: (2015) -
Giving AXL the axe: targeting AXL in human malignancy
por: Gay, Carl M, et al.
Publicado: (2017) -
The viceregency of Antonio María Bucareli in New Spain, 1717-1779 /
por: Bobb, Bernard E.
Publicado: (1970) -
World Trade in Medicinal Plants from Spanish America, 1717–1815
por: Gänger, Stefanie
Publicado: (2015)